Novo Nordisk acquires license for Argos Therapeutics technology
Under the terms of the agreement, Argos will receive up to $69 million, comprised of upfront and milestone payments, in addition to royalties on potential future sales of
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.